Experimental Drug Olorofim Shows Promise Against Severe Valley Fever
A new experimental drug called Olorofim is showing promise in treating severe cases of Valley Fever, a fungal infection increasingly prevalent in California. Researchers are studying its potential to eliminate the fungus, which could lead to FDA approval in the…
San Francisco Oakland San Jose, CA, July 30, 2026 —
An experimental drug, Olorofim, is demonstrating potential as a treatment for severe cases of Valley Fever, a fungal infection that has seen increasing prevalence in California. The development offers a new avenue of hope for individuals battling the most serious forms of the illness.
Researchers are actively studying Olorofim’s capacity to eradicate the fungus responsible for Valley Fever. Success in these studies could pave the way for seeking approval from the Food and Drug Administration (FDA) in the future.
Valley Fever, caused by the fungus Coccidioides, is endemic to specific regions of the Southwestern United States, including California. While many infections are mild and resolve on their own, a significant number of individuals develop severe or disseminated disease, which can be life-threatening and difficult to treat with existing therapies.
The ongoing research into Olorofim aims to address a critical unmet need for more effective treatments for severe Valley Fever. The current standard of care can have limitations, and the emergence of a new therapeutic option that shows promise in eliminating the fungus could significantly improve patient outcomes.
Further details regarding the specific stages of research, trial timelines, and the full scope of Olorofim’s efficacy and safety profile are expected as studies progress. The potential for FDA approval remains contingent on the outcomes of these ongoing investigations.
Story summarized from the original created by Keith Mizuguchi on ww2.kqed.org, see more information here.
